Avadel Pharmaceuticals PLC (NAS:AVDL) Stock News, Headlines & Updates
Avadel Pharmaceuticals PLC Stock News from GuruFocus
- 1
Aug 20, 2024
Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension
Marketwired • 7:00am
Aug 08, 2024
Avadel Pharmaceuticals (AVDL) Q2 2024 Earnings: EPS of ($0.14) and Revenue of $41.5 Million, Surpassing Estimates
GuruFocus Research • 6:36am
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Marketwired • 6:00am
Aug 01, 2024
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8
Marketwired • 7:00am
Jul 31, 2024
Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZâ„¢ Trial of LUMRYZâ„¢ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
Marketwired • 4:00pm
Jun 27, 2024
Avadel Pharmaceuticals to Join Russell 3000® Index
Marketwired • 4:00pm
May 30, 2024
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Marketwired • 7:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news